Ratings CervoMed Inc.

Equities

CRVO

US15713L1098

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
24.45 ^USD	-0.85%		+0.49%	+220.45%

Apr. 08	Canaccord Genuity Adjusts Price Target on CervoMed to $65 From $50, Maintains Buy Rating	MT
Mar. 29	CervoMed Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For several months, analysts have been revising their EPS estimates roughly upwards.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company's "enterprise value to sales" ratio is among the highest in the world.
The company appears highly valued given the size of its balance sheet.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
CERVOMED INC.	+220.45%	204M	-
VERTEX PHARMACEUTICALS INCORPORATED	+5.66%	109B	B+
REGENERON PHARMACEUTICALS, INC.	+11.23%	105B	B+
ARGENX SE	-0.38%	22.25B	B
BIONTECH SE	-12.15%	22.09B	B+
GENMAB A/S	-7.66%	18.68B	A-
WUXI APPTEC CO., LTD.	-36.52%	17.58B	A-
BEIGENE, LTD.	-10.09%	16.85B	B
NEUROCRINE BIOSCIENCES, INC.	+3.33%	13.76B	C+
SAREPTA THERAPEUTICS, INC.	+36.58%	12.46B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes